Komori
Financial results presentation4971MEC COMPANY LTD.Materials and Chemicals

Materials for the Briefing on Financial Results for the Third Quarter of the Fiscal Year Ending December 2025

2025年12月期第3四半期累計は、薬品の売上・出荷量の増加などにより増収増益となった。売上高は前年同期比9.5％増、営業利益は16.4％増で、通期予想は11月11日付で修正されている。

Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1305
¥ million (year-on-year increase in revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial results presentationThird quarter of the fiscal year ended December 202513 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥14,987 million+9.5%
Operating profit¥4,247 million+16.4%
Ordinary income¥4,361 million+17.9%
Net income¥3,329 million+26.7%
Selling, general and administrative expenses¥5,101 million
Gross Profit Margin62.4%（前年同期61.4%、+1.0ポイント）
Operating profit margin28.3%（前年同期26.7%、+1.6ポイント）
Results for the three months of the current quarter
Net Sales
¥5,600 million
Operating profit
¥1,806 million
Operating profit margin32.3%
Full-year earnings forecast
Net Sales
¥20,300 million
Operating profit
¥5,500 million
Ordinary income
¥5,650 million
Net income
¥4,300 million
Earnings per share
¥232.71
Operating profit margin27.1%
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales73.8%
Operating profit77.2%
Ordinary income77.2%
Net income77.4%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響（個別要因の金額は図に明記なし）
Operating profit薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（個別要因の金額は図に明記なし）
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
NTD¥4.76
RMB¥21.08
HKD¥19.48
THB¥4.22
EUR¥164.84
USD¥152.33
Business Environment回復基調にある半導体市況、IoT・AI・5G/6G等の進展を見込む
New initiatives
  • 北九州工場を新設し、最大生産能力2,500t/月、2026年12月稼働を予定
  • CZ・AP技術をインターポーザー、高周波基板、生成AI・データセンター関連分野へ展開
  • 新規事業の創出と既存技術の応用展開
Key KPIsA metric the company considers important as a management benchmark.
  • 薬品売上高¥14,559 million
    Year on year against the same period last year+11.6%
  • Shipment volume34,844 ton
    Year on year against the same period last year+10.9%
  • Overseas revenue ratio62.8 %
  • 連結生産能力8,100 t/month
    Year on year against the same period last year+12.5%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
出荷量は示されているが、単価との分解はNot disclosed
Segment results
Regional sales
Japan第3四半期3か月2,191百万円
Taiwan¥1,006 million
China1,835百万円
Europe¥269 million
Thailand¥297 million
品種別売上高
Chemicals第3四半期3か月5,534百万円
Machinery¥30 million
Materials¥33 million
Other¥2 million
Financial targets
ROE target10% or higher
Actual ROE12.1%（第3四半期）、通期予想15.3%
Number of stores and locations
店舗数はNot disclosed。生産拠点として国内2拠点、海外5拠点および北九州工場（予定）が記載されている。
Number of employees
Consolidated480 people
Standalone277 people
Record date2024年12月31日
Capital expenditures
¥2,069 million2025年12月期予想
Annual Dividend
Annual¥85 per share
Payout ratio
35% or more
DOE4.0% or more
Acquisition of treasury shares
状況に応じ機動的に実施。取得額の具体的な枠・期間はNot disclosed。
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredThird quarter of the fiscal year ended December 2025
Net Sales¥14,987 million (YoY +9.5%)
Operating profit¥4,247 million (YoY +16.4%)
Ordinary income¥4,361 million (YoY +17.9%)
Net income¥3,329 million (YoY +26.7%)
Gross Profit Margin62.4%（前年同期61.4%、+1.0ポイント）
Operating profit margin28.3%（前年同期26.7%、+1.6ポイント）
Selling, general and administrative expenses¥5,101 million
Results for the three months of the current quarterNet Sales ¥5,600 million / Operating profit ¥1,806 million / Operating profit margin 32.3%
Full-year earnings forecastNet Sales ¥20,300 million / Operating profit ¥5,500 million / Ordinary income ¥5,650 million / Net income ¥4,300 million / Earnings per share ¥232.71 / Operating profit margin 27.1%
Progress against full-year forecastNet Sales 73.8% / Operating profit 77.2% / Ordinary income 77.2% / Net income 77.4%
Segment resultsRegional sales Japan 第3四半期3か月2,191百万円 / Taiwan ¥1,006 million / China 1,835百万円 / Europe ¥269 million / Thailand ¥297 million / 品種別売上高 Chemicals 第3四半期3か月5,534百万円 / Machinery ¥30 million / Materials ¥33 million / Other ¥2 million
Breakdown of Factors Affecting the ChangeNet Sales 密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響（個別要因の金額は図に明記なし） / Operating profit 薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（個別要因の金額は図に明記なし）
Key KPIsIndicator name 薬品売上高 / Value ¥14,559 million / Year on year against the same period last year ¥11.6 million, Indicator name Shipment volume / Value 34,844 ton / Year on year against the same period last year 10.9 ton, Indicator name Overseas revenue ratio / Value 62.8 % / Year on year against the same period last year Not disclosed, Indicator name 連結生産能力 / Value 8,100 t/month / Year on year against the same period last year 12.5 t/month
Unit price and quantity metrics出荷量は示されているが、単価との分解はNot disclosed
Number of stores and locations店舗数はNot disclosed。生産拠点として国内2拠点、海外5拠点および北九州工場（予定）が記載されている。
Number of employeesConsolidated 480 people / Standalone 277 people / Record date 2024年12月31日
Assumptions Underlying the Business OutlookExchange rate NTD ¥4.76 / RMB ¥21.08 / HKD ¥19.48 / THB ¥4.22 / EUR ¥164.84 / USD ¥152.33 / Business Environment 回復基調にある半導体市況、IoT・AI・5G/6G等の進展を見込む
Financial targetsROE target 10% or higher / Actual ROE 12.1%（第3四半期）、通期予想15.3%
Annual DividendAnnual ¥85 per share / Interim Not disclosed / End of period Not disclosed
Payout ratioValue 35% or more / DOE 4.0% or more
Acquisition of treasury shares状況に応じ機動的に実施。取得額の具体的な枠・期間はNot disclosed。
Capital expenditures2,069 百万円（2025年12月期予想）
New initiatives北九州工場を新設し、最大生産能力2,500t/月、2026年12月稼働を予定, CZ・AP技術をインターポーザー、高周波基板、生成AI・データセンター関連分野へ展開, 新規事業の創出と既存技術の応用展開
Items this document does not state (6)
Self-assessment against the planRisk amount incorporated into the outlookMedium-term management plan targetsOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

薬品売上高が前年同期比11.6％増、出荷量が10.9％増となったこと。主要製品ではCZが16.4％増加した一方、V-Bond、EXE、SFは減少した。為替の影響は売上高23百万円減、営業利益11百万円減。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Materials for the Briefing on Financial Results for the Third Quarter of the Fiscal Year Ending December 2025 | MEC COMPANY LTD. (4971) timely disclosure | Komori